Literature DB >> 30190919

Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?

Lewis Au1, Aine O'Reilly1, James Larkin1.   

Abstract

Entities:  

Keywords:  anti-CTLA4; anti-PD-1; combination therapy; immunotherapy; metastatic melanoma

Year:  2017        PMID： 30190919      PMCID： PMC6094703          DOI： 10.2217/mmt-2017-0016

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  22 in total

1.  Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.

Authors:  Harsha A Ranganath; Timothy J Panella
Journal:  J Immunother       Date:  2015-06       Impact factor: 4.456

2.  Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Authors:  Lisa Zimmer; Susmitha Apuri; Zeynep Eroglu; Lisa A Kottschade; Andrea Forschner; Ralf Gutzmer; Max Schlaak; Lucie Heinzerling; Angela M Krackhardt; Carmen Loquai; Svetomir N Markovic; Richard W Joseph; Kelly Markey; Jochen S Utikal; Carsten Weishaupt; Simone M Goldinger; Vernon K Sondak; Jonathan S Zager; Dirk Schadendorf; Nikhil I Khushalani
Journal:  Eur J Cancer       Date:  2017-02-17       Impact factor: 9.162

3.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

4.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Authors:  Kim Margolin; Marc S Ernstoff; Omid Hamid; Donald Lawrence; David McDermott; Igor Puzanov; Jedd D Wolchok; Joseph I Clark; Mario Sznol; Theodore F Logan; Jon Richards; Tracy Michener; Agnes Balogh; Kevin N Heller; F Stephen Hodi
Journal:  Lancet Oncol       Date:  2012-03-27       Impact factor: 41.316

5.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

Authors:  Sandra P D'Angelo; James Larkin; Jeffrey A Sosman; Celeste Lebbé; Benjamin Brady; Bart Neyns; Henrik Schmidt; Jessica C Hassel; F Stephen Hodi; Paul Lorigan; Kerry J Savage; Wilson H Miller; Peter Mohr; Ivan Marquez-Rodas; Julie Charles; Martin Kaatz; Mario Sznol; Jeffrey S Weber; Alexander N Shoushtari; Mary Ruisi; Joel Jiang; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

6.  Prognostic score for patients with advanced melanoma treated with ipilimumab.

Authors:  Stefan Diem; Benjamin Kasenda; Juan Martin-Liberal; Alexander Lee; Dharmisha Chauhan; Martin Gore; James Larkin
Journal:  Eur J Cancer       Date:  2015-11-18       Impact factor: 9.162

7.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

8.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Authors:  Douglas B Johnson; Ryan J Sullivan; Patrick A Ott; Matteo S Carlino; Nikhil I Khushalani; Fei Ye; Alexander Guminski; Igor Puzanov; Donald P Lawrence; Elizabeth I Buchbinder; Tejaswi Mudigonda; Kristen Spencer; Carolin Bender; Jenny Lee; Howard L Kaufman; Alexander M Menzies; Jessica C Hassel; Janice M Mehnert; Jeffrey A Sosman; Georgina V Long; Joseph I Clark
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

Review 9.  Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature.

Authors:  A Jose; P Yiannoullou; S Bhutani; H Denley; M Morton; M Picton; A Summers; D van Dellen; T Augustine
Journal:  Transplant Proc       Date:  2016-11       Impact factor: 1.066

10.  PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV.

Authors:  Diwakar Davar; Melissa Wilson; Chelsea Pruckner; John M Kirkwood
Journal:  Case Rep Oncol Med       Date:  2015-09-10
View more
  1 in total

1.  PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide.

Authors:  Tiesuo Zhao; Tian Wei; Jing Guo; Yangeng Wang; Xiangyi Shi; Sheng Guo; Xiaolong Jia; Huijie Jia; Zhiwei Feng
Journal:  Cell Death Dis       Date:  2019-02-18       Impact factor: 8.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.